Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody - PubMed (original) (raw)

Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody

N Sullivan et al. J Virol. 1993 Jun.

Abstract

The contributions of the first and second variable regions of the human immunodeficiency virus type 1 gp120 glycoprotein to envelope glycoprotein structure, function, and recognition by a neutralizing antibody were studied. Several mutants with substitutions in the V2 loop demonstrated complete dissociation of the gp120 and gp41 glycoproteins, suggesting that inappropriate changes in V2 conformation can affect subunit assembly. Some glycoproteins with changes in V1 or V2 were efficiently expressed on the cell surface and were able to bind CD4 but were deficient in syncytium formation and/or virus entry. Recognition of gp120 by the neutralizing monoclonal antibody G3-4 was affected by particular substitutions affecting residues 176 to 184 in the V2 loop. These results suggest that the V1/V2 variable regions of the human immunodeficiency virus type 1 gp120 glycoprotein play a role in postreceptor binding events in the membrane fusion process and can act as a target for neutralizing antibodies.

PubMed Disclaimer

Cited by

T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection.
Sakaida H, Hori T, Yonezawa A, Sato A, Isaka Y, Yoshie O, Hattori T, Uchiyama T. Sakaida H, et al. J Virol. 1998 Dec;72(12):9763-70. doi: 10.1128/JVI.72.12.9763-9770.1998. J Virol. 1998. PMID: 9811711 Free PMC article.
HIV-1 envelope subregion length variation during disease progression.
Curlin ME, Zioni R, Hawes SE, Liu Y, Deng W, Gottlieb GS, Zhu T, Mullins JI. Curlin ME, et al. PLoS Pathog. 2010 Dec 16;6(12):e1001228. doi: 10.1371/journal.ppat.1001228. PLoS Pathog. 2010. PMID: 21187897 Free PMC article.
Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.
Zolla-Pazner S, Cardozo T. Zolla-Pazner S, et al. Nat Rev Immunol. 2010 Jul;10(7):527-35. doi: 10.1038/nri2801. Nat Rev Immunol. 2010. PMID: 20577269 Free PMC article. Review.
Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.
Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE. Pastore C, et al. J Virol. 2006 Jan;80(2):750-8. doi: 10.1128/JVI.80.2.750-758.2006. J Virol. 2006. PMID: 16378977 Free PMC article.
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, Zolla-Pazner S. Gorny MK, et al. J Virol. 1994 Dec;68(12):8312-20. doi: 10.1128/JVI.68.12.8312-8320.1994. J Virol. 1994. PMID: 7525987 Free PMC article.

References

1. J Acquir Immune Defic Syndr. 1991;4(9):923-4 - PubMed
1. J Virol. 1991 Nov;65(11):6188-93 - PubMed
1. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8949-52 - PubMed
1. Science. 1991 Oct 4;254(5028):105-8 - PubMed
1. J Virol. 1992 Jan;66(1):524-33 - PubMed

Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody - PubMed (original) (raw)